Class: Vaccine, Inactivated, Bacterial
Dosage Forms. Suspension for Intramuscular Injection: For Adults, available in combination with tetanus and diphtheria toxoids (Tdap); for Children, available in combination with tetanus and diphtheria toxoids (DTaP), and in combination with other pediatric vaccines
Common FDA Label Indication, Dosing, and Titration.
1. Prevention of tetanus: Children, all infants at age 2, 4, 6, and 12-15 mo, and a fifth dose at age 4-6 y, as primary series of DTaP; Adults, at age 11-12 y, Tdap
Off-Label Uses. None
Drug Characteristics: Tetanus Toxoid
Medication Safety Issues: Tetanus Toxoid
Drug Interactions: Tetanus Toxoid
Adverse Reactions: Tetanus Toxoid
Efficacy Monitoring Parameters. Prevention of tetanus, although antibody concentrations might be measured; routine measurement for vaccine response is not recommended.
Toxicity Monitoring Parameters. Monitor for syncope, temperature after administration.
Key Patient Counseling Points. Return to provider for each dose in the series.
Clinical Pearls. Use the same brand of vaccine to complete the entire series, if possible. After childhood immunization, adults should receive Td (tetanus with diptheria) vaccination every 10 y. Individuals with wounds requiring medical attention should be vaccinated with Td if vaccination status is inadequate or unknown, or if >5 y since last vaccination.